Effect of fluticasone furoate (FF)/vilanterol (VI) compared with VI on acute exacerbations of COPD (AECOPD): A post-hoc analysis by baseline airflow obstruction
David Leather (Crewe, United Kingdom), David Leather, Louisa Yates, Amy Newlands
|   |
Systemic inhibition of p38 MAPK improves lung function and inflammatory markers in moderate-severe COPD
Nicholas Clarke (Cambridge, United States of America), Spencer Danto, Grant Langdon, Negin Shojaee, Jared Christensen, Nick Clarke, Lisa Tan, Christelle Perros-Huguet
| |
Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency
Michael Tortorici (King of Prussia, United States of America), Michael A. Tortorici, Zhenling Yao, James A. Rogers, Oliver Vit, Martin Bexon, Robert Sandhaus, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, N. Gerard McElvaney, Kenneth R. Chapman, Jonathan Edelman
| |
Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency
Michael Tortorici (King of Prussia, United States of America), Michael A. Tortorici, Oliver Vit, Martin Bexon, Robert Sandhaus, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, N. Gerard McElvaney, Kenneth R. Chapman, Jonathan Edelman
| |
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Dave Singh (Manchester, United Kingdom), Dave Singh, M. Reza Maleki-Yazdi, Lee Tombs, Ian Naya, Ahmar Iqbal
| |
QVA149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e-diary: The SHINE study
Hanns-Christian Tillmann (Basel, Switzerland), Hanns-Christian Tillmann, Ieuan Jones, Robert Fogel, Donald Banerji
| |
Corticosteroids improve lung function and quality of life in subjects with biomass fuel (BMF) smoke exposures induced COPD
Kuldeep Mandani (Pune, Maharashtra, India), Kuldeep Mandani, Kanchan Pyasi, Vandana Vincent, Jyoti Londhe, Sapna Madas, Bill Brashier, Sundeep Salvi, Peter Barnes
| |
Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients
Edward Kerwin (Medford, United States of America), Edward Kerwin, Thomas Siler, Lee Tombs, Ana R. Sousa, Karen Singletary, Alison Church
| |
Implications of under treatment of stable COPD (SAVING study)
Antonio Corrado (Firenze, Italy), Antonio Corrado, Andrea Rossi, On Behalf of SAVING/AIPO Study Group
| |
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Lorcan McGarvey (Belfast, United Kingdom), Lorcan McGarvey, Roland Buhl, Lawrence Korducki, Valeria C. Amatto, Kay Tetzlaff, Leif Bjermer
| |
Effect of umeclidinium/vilanterol (UMEC/VI) on inspiratory capacity/total lung capacity ratio in hyperinflated COPD patients
Sally J. Singh (Leicester, United Kingdom), Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H. Riley
| |
Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease: A nationwide population-based study
Vincent Yi-Fong Su (Taipei, Taiwan), Vincent Yi-Fong Su
| |
Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study
Roberto Walter Dal Negro (Verona, Italy), Roberto W. Dal Negro, Martin Iversen, Peter M.A. Calverly
| |
Onset of action of aclidinium (ACL), glycopyrronium (GLY) and tiotropium (TIO): A comparison in COPD patients
Paola Rogliani (Rome, Italy), Paola Rogliani, Roberto Lipsi, Josuel Ora, Gabriella Lucà, Luigino Calzetta, Mario Cazzola
| |
Anticholinergic treatment does not affect toll-like receptor 3-induced antiviral immune response in COPD bronchial epithelial cells
Seil Sagar (Lund, Sweden), Seil Sagar, Mandy Menzel, Leif Bjermer, Lena Uller
| |
Investigator-reported vs adjudicated cause of death in the TIOSPIR™ trial
Robert Wise (Baltimore, United States of America), Robert Wise, Peter Kowey, George Austen, Andy Lawton, Achim Mueller, Norbert Metzdorf, Andy Fowler, Lorcan McGarvey
| |
Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity
Anthony D. D'Urzo (Toronto, Canada), Anthony D. D’Urzo, Dave Singh, Edward Kerwin, Hassan Lakkis, Ferran Chuecos, Gonzalo De Miquel
| |
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Peter M.A. Calverley (Liverpool, United Kingdom), Peter Calverley, Kay Tetzlaff, Achim Mueller, Norbert Metzdorf, Bernd Disse, Ronald Dahl
| |